Annovis Bio Inc (ANVS)
NYSEHealth CareBiotechnologySnapshot 2026-09-04
$1.39+0.72%
Close 2026-09-04 · 1-day change
NYSEHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ANVS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ANVS — earnings miss
Dated 2026-05-15
Results of Operations and Financial Condition. On May 15, 2026, Annovis Bio, Inc. (the “Registrant”) issued a press release reporting earnings for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99 hereto and incorporated herein by reference.
Why it matters: If the NDA is approved, it could help sales of buntanetap.
Supportive ifManagement plans to submit the NDA soon after the Q1 2027 data.
Worry ifManagement may delay or cancel the NDA due to bad data.
Why it matters: New funds are needed to support clinical programs as losses increase.
Watch forManagement says they sold stock successfully to raise more than $10M.
Also watch forNo news on raising money or more delays in funding.
Why it matters: Good plans for NDA submissions could speed up getting the treatment to market.
Supportive ifAnnovis says it is ready to submit NDAs after the Q1 2027 data.
Worry ifThe company might delay NDA plans or not meet regulatory rules.
Why it matters: This data will show if the treatment helps with symptoms of Alzheimer's. Positive results could lead to regulatory submissions.
Supportive ifThe latest data shows big gains in ADAS-Cog13 and ADCS-iADL scores.
Worry ifThe data shows no big changes in the main endpoints.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$283 on $10,000 · ±2.8% | How much price usually moves either way. |
| Bad day | $790 loss on $10,000 · 7.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,294 loss on $10,000 · 72.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Starting this study shows commitment to patient care. It could also improve data collection.
Supportive ifThe study for Alzheimer’s will start in October 2026.
Worry ifThe OLE study does not start on time. This may cause delays in clinical development.
Why it matters: High cash burn could signal financial stress. Investors will want to see if management is controlling costs.
Worry ifCash burn goes down compared to past quarters. This shows better cost management.
Less concerning ifCash burn goes up or stays high. This shows ongoing financial problems.
Why it matters: A successful capital raise is key to pay for clinical trials and control cash flow.
Watch forAnnovis completes the public offering. It gets the money needed for clinical work.
Also watch forAnnovis does not finish the offering or cuts the size of the offering.
Why it matters: Starting this study lets patients keep getting treatment. It shows care for patients and data.
Supportive ifAnnovis says the AD OLE study started in October 2026.
Worry ifThe AD OLE study is delayed or canceled.
Why it matters: This data readout will inform the potential for a second NDA submission. It is key for understanding the long-term effects of the drug.
Supportive ifData shows strong disease-modifying effects. This supports the drug's long-term use.
Worry ifData shows weak effects on the disease. This may hurt future regulatory filings.
Why it matters: This data will show how effective buntanetap is for treating early Alzheimer's. Positive results could lead to a New Drug Application (NDA) submission.
Supportive ifThe Phase 3 trial shows that buntanetap helps patients think better.
Worry ifThe data shows no real change in thinking skills compared to placebo.
Why it matters: Good data can help investors feel better. It can also help get more funding.
Supportive ifManagement shares good results from clinical trials in Q1 2027.
Worry ifManagement shares bad results from clinical trials in Q1 2027.
Why it matters: It is important for management to control cash use for the company's future.
Worry ifManagement reports cash burn reduced to below $9 million in the next quarter.
Less concerning ifCash burn remains at or above $9 million.
Why it matters: Raising money will help pay for clinical trials and operations. This helps financial stability.
Supportive ifThe public offering is done. This gives needed money for clinical development.
Worry ifThe offering fails to close or is much smaller. This suggests possible financial trouble.
Why it matters: Enrollment progress is key to seeing how well the treatment works for Parkinson's disease.
Supportive ifEnrollment hits the target of 500 patients. This shows strong interest and possible effectiveness.
Worry ifEnrollment stops or goes down. This suggests problems in getting patients or their interest.
Why it matters: The 6-month data will show if the treatment is effective. This is crucial for future funding and regulatory approval.
Supportive ifTopline data will come out in Q1 2027. It will confirm how well the treatment works.
Worry ifData shows no real improvement in thinking or function. This raises doubts about how well the treatment works.
Why it matters: A big drop in cash could hurt the company's ability to fund trials and operations.
Worry ifCash and cash equivalents are reported above $18 million.
Less concerning ifCash and cash equivalents fall below $18 million.
Why it matters: Completing this enrollment is key. It shows how buntanetap affects Parkinson's over time.
Supportive ifAnnovis announces full enrollment for the PD OLE study by the end of Q4 2026.
Worry ifEnrollment is still not done after Q4 2026. This may mean trouble finding patients.